CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	$0.1660	+8.30%	364
16/07/26	$0.1533	+9.49%	743
15/07/26	$0.1400	-3.27%	3,513
14/07/26	$0.1447	-25.28%	1,890
13/07/26	$0.1937	+33.49%	650

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:32:05 17/07/2026 +04			5-day change	1st Jan Change
0.1660 ^USD	+8.30%		+14.40%	-80.47%

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	3.41M 2.98M 2.75M 2.54M 4.78M 329M 4.89M 32.89M 12.94M 161M 12.81M 12.53M 554M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	25.27M 22.08M 20.37M 18.78M 35.4M 2.43B 36.18M 244M 95.79M 1.19B 94.89M 92.81M 4.1B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-15	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-21	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-21	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

1 week	+14.40%
Current month	-2.35%
1 month	+15.60%
3 months	+21.17%
6 months	-82.65%
Current year	-80.47%

CASI Pharmaceuticals, Inc. Stock Nasdaq

Stocks

CASI

KYG1933S1012

Pharmaceuticals

Valuation: CASI Pharmaceuticals, Inc.

Chart: CASI Pharmaceuticals, Inc.

Latest news : CASI Pharmaceuticals, Inc.

Press Releases: CASI Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CASI Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 week	0.13	0.19
1 month	0.12	0.29
3 years	0.05	8.48
5 years	0.05	17.4
10 years	0.05	88.92

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
David Cory BRD	Director/Board Member	62	21/07/2025
James Huang CHM	Chairman	60	17/11/2025
Yue Wu BRD	Director/Board Member	62	01/04/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CASI PHARMACEUTICALS, INC.	+8.30%	+14.40%	-87.13%	-93.74%	3.41M
ELI LILLY AND COMPANY	+0.85%	-0.80%	+52.79%	+159.97%	1,051B
JOHNSON & JOHNSON	+1.23%	-1.53%	+54.58%	+59.41%	609B
ABBVIE INC.	+0.04%	+2.58%	+34.47%	+84.84%	450B
ROCHE HOLDING AG	+0.78%	-0.71%	+29.28%	+23.25%	330B
NOVARTIS AG	+1.41%	+0.58%	+35.44%	+40.53%	284B
ASTRAZENECA PLC	-0.27%	-1.87%	+22.34%	+19.92%	263B
NOVO NORDISK A/S	-1.76%	+2.37%	-20.43%	-38.01%	223B
AMGEN INC.	-1.42%	+0.80%	+24.27%	+57.85%	198B
GILEAD SCIENCES, INC.	-1.48%	+3.43%	+24.08%	+70.06%	167B
Average	-0.07%	+0.54%	+16.97%	+38.41%	397.23B
Weighted average by Cap.	+0.37%	+0.02%	+37.51%	+78.76%

	2024	2025
Net sales	28.54M 24.94M 23.01M 21.21M 39.98M 2.75B 40.87M 275M 108M 1.35B 107M 105M 4.63B	20.71M 18.1M 16.7M 15.4M 29.02M 1.99B 29.66M 200M 78.52M 977M 77.78M 76.08M 3.36B
Net income	-39.26M -34.31M -31.66M -29.18M -55M -3.78B -56.22M -378M -149M -1.85B -147M -144M -6.37B	-48.06M -42M -38.75M -35.72M -67.33M -4.63B -68.82M -463M -182M -2.27B -180M -177M -7.8B
Net Debt	6.05M 5.29M 4.88M 4.5M 8.48M 583M 8.66M 58.31M 22.94M 285M 22.72M 22.22M 982M	21.85M 19.1M 17.62M 16.24M 30.62M 2.1B 31.3M 211M 82.85M 1.03B 82.07M 80.27M 3.55B